Benefits
Immune modulation
Beta-glucans from reishi activate macrophages, NK cells, and dendritic cells. The main cited human evidence is a Cochrane review (Jin 2016) of reishi as an adjunct in cancer care, which reported only low-quality evidence with some immune signal; reishi is not a cancer treatment, and this does not establish a general immune-boosting effect in healthy people.
Stress adaptation and sleep
Triterpenoids modulate the HPA axis and have GABA-like effects on the CNS, and are proposed to promote calm. Reishi is traditionally used as a calming adaptogen in TCM for nervous system support, but human evidence for sleep or anxiety benefits is preliminary and uncited.
Antioxidant protection
Rich in polyphenols and triterpenoids that scavenge reactive oxygen species and upregulate endogenous antioxidant enzymes (SOD, catalase, GPx), a proposed antioxidant action that is mechanistic and has not been established in human trials of reishi.
Cardiovascular support
Ganoderic acids inhibit cholesterol synthesis and platelet aggregation. These cardiovascular effects are mechanistic and uncited; reductions in blood pressure or LDL cholesterol have not been demonstrated in controlled human trials of reishi.
Mechanism of action
Beta-glucan receptor activation
Reishi beta-glucans bind to Dectin-1 receptors and TLR-2 on innate immune cells, activating NF-κB signaling and triggering production of pro-inflammatory cytokines, NK cell activation, and enhanced phagocytosis.
Triterpenoid adaptogenic activity
Ganoderic acids modulate cortisol secretion, inhibit inflammatory enzymes (COX-1/2), and interact with GABA-A receptors to produce calming and sleep-promoting effects.
HMG-CoA reductase inhibition
Certain ganoderic acids inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis — same target as statin drugs — a proposed mechanism; lipid-lowering effects of reishi have not been established in human trials.
Clinical trials
Clinical trial of reishi (Ganoderma lucidum) polysaccharide extract vs placebo in 48 advanced colorectal cancer patients over 12 weeks. Outcomes: NK cell activity, lymphocyte counts, cytokines.
48 advanced colorectal cancer patients.
Reishi modestly increased NK cell counts and lymphocyte populations vs placebo. Critical context: cancer patients should never replace evidence-based oncology with reishi; immune-modulating supplements during active treatment should be coordinated with oncologist. Some immune supplements may interact with chemotherapy/immunotherapy. Reishi is at most adjunctive in supportive care.
Clinical trial examining reishi extract supplementation in breast cancer patients undergoing endocrine therapy.
Breast cancer patients.
Modest improvements in fatigue, anxiety, QoL scores; higher NK cell activity vs control. Note: same caveat — coordinate with oncology team.